623 Results

People

  1. Drilon
    Drilon
  2. Ladanyi
    Ladanyi
  3. Kris
    Kris
  4. Arcila
    Arcila
  5. Hyman
    Hyman
  6. Rudin
    Rudin
  7. Riely
    Riely
  8. Li
    Li
  9. Offin
    Offin
  10. Berger
    Berger

Groups

  1. Department of Medicine (623)
  2. Solid Tumor Oncology Division (623)
  3. Thoracic Oncology (623)
  4. Department of Pathology and Laboratory Medicine (205)
  5. GSK Faculty (186)
  6. Human Oncology and Pathogenesis Program (156)
  7. Tow Center for Developmental Oncology (TCDO) (128)
  8. Weinberg Fellows (124)
  9. Early Drug Development Service (111)
  10. Sloan Kettering Institute Postdocs (105)
  1. "Alexander Drilon"
Formats
  1. Meeting Abstract (371)
  2. Journal Article (213)
  3. Review (23)
  4. Editorial (6)
  5. Correspondence (3)
  6. Book Section (2)
  7. Research Letter (2)
  8. Book Whole (1)
  9. Guidelines (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (623)
  2. Solid Tumor Oncology Division (623)
  3. Thoracic Oncology (623)
  4. Department of Pathology and Laboratory Medicine (205)
  5. GSK Faculty (186)
  6. Human Oncology and Pathogenesis Program (156)

More Groups

People
  1. Alexander Drilon (623)
  2. Marc Ladanyi (121)
  3. Mark Kris (89)
  4. Maria Arcila (82)
  5. David Hyman (78)
  6. Bob Li (64)

More People

Years
  1. 2025 (8)
  2. 2024 (61)
  3. 2023 (67)
  4. 2022 (85)
  5. 2021 (76)
  6. 2020 (81)

More Years

Publications
  1. Journal of Clinical Oncology (137)
  2. Annals of Oncology (94)
  3. Journal of Thoracic Oncology (82)
  4. Clinical Cancer Research (31)
  5. Cancer Research (23)
  6. JCO Precision Oncology (23)

More Publications

Publishers
  1. American Society of Clinical Oncology (162)
  2. Elsevier Inc. (116)
  3. Oxford University Press (111)
  4. American Association for Cancer Research (76)
  5. Nature Publishing Group (27)
  6. S. Karger AG (23)

More Publishers

Results (623)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genetic ancestry-based differences in biomarker-based eligibility for precision oncology therapies
    Journal Article

    Arora, K.; Suehnholz, S. P.; Zhang, H.; Ostrovnaya, I.; Kundra, R.; Nandakumar, S.; Nissan, M. H.; Brannon, A. R.; Bandlamudi, C.; Ladanyi, M.; more...
    JAMA Oncology (2025)

    Fulltext@MSK | Save
  • Targeting ROS1 rearrangements in non–small cell lung cancer: Current insights and future directions
    Review

    Desilets, A.; Repetto, M.; Yang, S. R.; Drilon, A.
    Cancer (2025)

    Fulltext@MSK | Save
  • Population-adjusted indirect treatment comparisons of repotrectinib among patients with ROS1+ NSCLC
    Journal Article

    Wolf, J.; Goring, S.; Lee, A.; Cho, B. C.; Drilon, A.; Yuan, Y.; Ayers, D.; Lozano-Ortega, G.; Korol, E. E.; Korpach, S. G.; more...
    Cancers (2025)

    Fulltext@MSK | Save
  • Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer
    Journal Article

    Qi, C.; Shen, L.; Andre, T.; Chung, H. C.; Cannon, T. L.; Garralda, E.; Italiano, A.; Rieke, D. T.; Liu, T.; Burcoveanu, D. I.; more...
    European Journal of Cancer (2025)

    Fulltext@MSK | Save
  • Efficacy of zenocutuzumab in NRG1 fusion-positive cancer
    Journal Article

    Schram, A. M.; Goto, K.; Kim, D. W.; Macarulla, T.; Hollebecque, A.; O'Reilly, E. M.; Ou, S. H. I.; Rodon, J.; Rha, S. Y.; Nishino, K.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • Mucocutaneous adverse events in patients with cancer treated with the highly selective RET kinase inhibitor selpercatinib (LOXO-292)
    Journal Article

    Reingold, R. E.; Parisi, R.; Harada, G.; Moy, A. P.; Dranitsaris, G.; Francis, J. H.; Canestraro, J.; Lester, J. A.; Kaplanis, L. A.; Liu, D.; more...
    JTO Clinical and Research Reports (2025)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of central nervous system tumors harboring NTRK gene fusions
    Journal Article

    Lamoureux, A. A.; Fisher, M. J.; Lemelle, L.; Pfaff, E.; Amir-Yazdani, P.; Kramm, C.; De Wilde, B.; Kazanowska, B.; Hutter, C.; Pfister, S. M.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Next-generation sequencing for HLA genotype screening and matching to HLA-restricted therapies
    Research Letter

    Gormally, M. V.; Chen, M. F.; Noronha, A. M.; Panageas, K.; Reynolds, M.; Kohlasch, K.; Novak, B.; Kee-Velez, T.; Clarke, N.; Eubank, M.; more...
    JAMA Oncology (2025)

    Fulltext@MSK | Save
  • METxMET bispecific antibody davutamig (REGN5093) for MET-altered advanced non-small cell lung cancer (aNSCLC): Update from a first-in-human (FIH) study
    Meeting Abstract

    Cho, B. C.; Ahn, M. J.; Kim, T. M.; Kim, S. W.; Han, J. Y.; Kim, C.; Shim, B.; Ricordel, C.; Drilon, A. E.; Pujol, J. L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC
    Meeting Abstract

    Krebs, M. G.; Lu, S.; Fan, Y.; Yu, Y.; Drilon, A. E.; Siena, S.; Xue, C.; Bradley, D.; Hu, X.
    Annals of Oncology (2024)

    Fulltext@MSK | Save